STOCK TITAN

Supernus (SUPN) Insider Exercise and 10b5-1 Sales Total $11.19M

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 29,513 shares of common stock through Morgan Stanley Smith Barney on 09/23/2025 to be executed on the NASDAQ. The shares were acquired and paid for on 09/23/2025 by exercise of stock options, with payment in cash. The filing also lists multiple Rule 10b5-1 sales by Jack A. Khattar over August–September 2025, showing several transactions and gross proceeds. The notice includes the seller's representation regarding absence of undisclosed material information.

Positive

  • None.

Negative

  • Multiple recent 10b5-1 sales totaled approximately $11,194,631.04 in gross proceeds across transactions dated 08/06/2025–09/22/2025, as listed in the filing

Insights

TL;DR Insider exercised options and proposes an immediate sale of 29,513 shares; several prior 10b5-1 sales occurred in Aug–Sep 2025.

The filing shows a routine Form 144 notice: shares were acquired by exercise of stock options and payment was made in cash the same day, indicating these are not open-market transfers from inherited or gifted shares. The broker listed is Morgan Stanley Smith Barney and the transaction is slated for NASDAQ. The document documents numerous recent 10b5-1 sales by Jack A. Khattar, reflecting ongoing systematic disposition activity rather than a single ad-hoc sale.

TL;DR This is a compliance-focused disclosure showing planned insider sales and prior 10b5-1 transactions, with standard attestations.

The notice includes the required attestation that the seller is not aware of undisclosed material adverse information and references a broker and planned sale date. The presence of multiple 10b5-1 entries demonstrates use of pre-arranged trading plans, which is consistent with governance best practices for scheduled insider sales. No new corporate actions or governance changes are disclosed in this filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the SUPN Form 144 report?

The filing reports a proposed sale of 29,513 common shares to be sold on 09/23/2025 on NASDAQ; the shares were acquired by exercise of stock options and paid in cash on 09/23/2025.

Who is the broker handling the proposed SUPN sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Has the insider recently sold SUPN shares?

Yes. The filing lists multiple Rule 10b5-1 sales by Jack A. Khattar between 08/06/2025 and 09/22/2025, with aggregate gross proceeds of approximately $11,194,631.04.

How were the 29,513 shares acquired?

The shares were acquired on 09/23/2025 through exercise of stock options, and payment was made in cash on the same date, per the filing.

Does the filer assert possession of undisclosed material information?

By signing the form, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.